IP Library › Granted Patent US 12,390,517
Granted Patent B2
US 12,390,517 · App. 17/416,271 · Granted Aug 19, 2025

Compositions, methods and uses for eliciting an immune response

Inventors: Freda E.-C. Jen (Nathan, AU); Kate Seib (Nathan, AU); Evgeny Semchenko (Nathan, AU); Michael Jennings (Nathan, AU)
Assignee: GRIFFITH UNIVERSITY
A61K39/095C12N15/86A61K2039/55566A61K2039/55577A61K2039/575A61K2039/6037A61K2039/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,390,517
App. No.
17/416,271
Granted
Aug 19, 2025
Kind
B2
Abstract

This invention relates generally to polynucleotides, polypeptides, compositions, methods and uses for eliciting an immune response to Neisseria , methods for immunizing a subject against a Neisseria infection, and methods for preventing and/or treating a Neisseria infection in a subject. More particularly, the invention relates to antigenic Neisseria polypeptides and encoding polynucleotides, and related uses and methods, including use for preparing compositions and medicaments for eliciting an immune response to Neisseria , for immunizing a subject against a Neisseria infection, and for preventing and/or treating a Neisseria infection in a subject. The invention also relates to methods for producing therapeutic anti- Neisseria antigen-binding molecules, and therapeutic uses of those antigen-binding molecules.

Claims (40)

1. A method for eliciting an immune response to N. gonorrhoeae or N. meningitidis in a subject, comprising administering to the subject a composition, comprising:

a recombinant or synthetic methionine sulfoxide reductase A/B (MsrA/B) polypeptide, or a recombinant or synthetic polynucleotide encoding the MsrA/B polypeptide, and an adjuvant; or

a viral vector comprising a polynucleotide encoding the MsrA/B polypeptide;

wherein the MsrA/B polypeptide:

(a) lacks 1 to 16 amino acids from the N-terminus of a full-length MsrA/B polypeptide, wherein the full-length MsrA/B polypeptide comprises the amino acid sequence set forth in SEQ ID NO:1 or an amino acid sequence having at least 95% sequence identity to the sequence set forth in SEQ ID NO:1; or

(b) is an antigenic fragment of a polypeptide defined in (a), wherein the antigenic fragment is at least 30 amino acids long.

2. The method of claim 1 , wherein the MsrA/B polypeptide comprises amino acids corresponding to amino acids 17-522 of SEQ ID NO:1.

3. The method of claim 1 , wherein the antigenic fragment comprises all or a portion of the MsrA domain.

4. The method of claim 1 , wherein the antigenic fragment comprises all or a portion of amino acids corresponding to amino acids 181-362 or 199-354 of SEQ ID NO:1.

5. The method of claim 1 , wherein the antigenic fragment comprises all or a portion of the MsrB domain.

6. The method of claim 1 , wherein the antigenic fragment comprises all or a portion of amino acids corresponding to amino acids 375-522 or 383-506 of SEQ ID NO:1.

7. The method of claim 1 , wherein the antigenic fragment comprises all or a portion of the thioredoxin domain.

8. The method of claim 1 , wherein the antigenic fragment comprises all or a portion of amino acids corresponding to amino acids 17-174 of SEQ ID NO:1.

9. The method of claim 1 , wherein the full-length MsrA/B polypeptide comprising an amino acid sequence having at least 95% sequence identity to the sequence set forth in SEQ ID NO:1 is selected from among SEQ ID NO:9-12.

10. The method of claim 1 , wherein the MsrA/B polypeptide is linked to a T helper cell epitope.

11. The method of claim 1 , wherein the MsrA/B polypeptide is linked to a carrier protein.

12. The method of claim 10 , wherein the carrier protein is selected from among tetanus toxoid, diphtheria toxoid and CRM-197.

13. The method of claim 5 , wherein the adjuvant is selected from among an aluminium salt, a water-in-oil emulsion, an oil-in-water emulsion, a toll like receptor (TLR) agonist, a saponin-based adjuvant, a liposome, a virosome, a virus-like particle (VLP), a cytokine, a chemokine and a growth factor.

14. The method of claim 13 , wherein the oil-in-water emulsion comprises squalene.

15. The method of claim 13 , wherein the saponin-based adjuvant comprises saponins or saponin derivatives from Quillaja saponaria, Panax ginseng Panax notoginseng, Panax quinquefolium, Platycodon grandiflorum, Polygala senega, Polygala tenuifolia, Quillaja brasiliensis, Astragalus membranaceus or Achyranthes bidentate.

16. The method of claim 13 , wherein the saponin-based adjuvant is an iscom or iscom matrix.

17. The method of claim 13 , wherein the TLR agonist is a TLR1, TLR2, TLR3, TLR4, TLR5, TLR7, TLR8, TLR9 and/or TLR10 agonist.

18. The method of claim 1 , further comprising at least one additional antigen.

19. The method of claim 18 , wherein the at least one additional antigen comprises a N. gonorrhoeae antigen.

20. The method of claim 19 , wherein the N. gonorrhoeae antigen is selected from among PilC, PilQ, Opa, AniA, TdfJ, PorB, Lst, TbpB, TbpA, OmpA, OpcA, MetQ, MtrE and the 2C7 epitope or epitope mimetic.

21. The method of claim 18 , wherein the at least one additional antigen comprises a N. meningitidis antigen.

22. The method of claim 21 , wherein the N. meningitidis antigen is selected from among NadA, fHbp, NHBA, GNA1030, GNA2091, HmbR, NspA, Nhha, App, Omp85, TbpA, TbpB, Cu,Zn-superoxide dismutase and a capsular polysaccharides or oligosaccharides from meningococcal serogroup A, C, W135 or Y.

23. The method of claim 1 , wherein the viral vector is selected from a retrovirus, adenovirus, adeno-associated virus (AAV), herpes virus, alphavirus, astrovirus, coronavirus, orthomyxovirus, papovavirus, paramyxovirus, parvovirus, picornavirus, poxvirus, and togavirus vector.

24. A method for inhibiting the development or progression of a N. gonorrhoeae and/or N. meningitidis infection in a subject, comprising administering to the subject a composition, comprising:

a recombinant or synthetic methionine sulfoxide reductase A/B (MsrA/B) polypeptide, or a recombinant or synthetic polynucleotide encoding the MsrA/B polypeptide, and an adjuvant; or

a viral vector comprising a polynucleotide encoding the MsrA/B polypeptide; wherein the MsrA/B polypeptide:

(a) lacks 1 to 16 amino acids from the N-terminus of a full-length MsrA/B polypeptide, wherein the full-length MsrA/B polypeptide comprises the amino acid sequence set forth in SEQ ID NO:1 or an amino acid sequence having at least 95% sequence identity to the sequence set forth in SEQ ID NO:1; or

(b) is an antigenic fragment of a polypeptide defined in (a), wherein the antigenic fragment is at least 30 amino acids long.

25. A method for treating a N. gonorrhoeae and/or N. meningitidis infection in a subject, comprising administering to the subject a composition, comprising:

a recombinant or synthetic methionine sulfoxide reductase A/B (MsrA/B) polypeptide, or a recombinant or synthetic polynucleotide encoding the MsrA/B polypeptide, and an adjuvant; or

a viral vector comprising a polynucleotide encoding the MsrA/B polypeptide; wherein the MsrA/B polypeptide:

(a) lacks 1 to 16 amino acids from the N-terminus of a full-length MsrA/B polypeptide, wherein the full-length MsrA/B polypeptide comprises the amino acid sequence set forth in SEQ ID NO:1 or an amino acid sequence having at least 95% sequence identity to the sequence set forth in SEQ ID NO:1; or

(b) is an antigenic fragment of a polypeptide defined in (a), wherein the antigenic fragment is at least 30 amino acids long.

26. The method of claim 13 , wherein the TLR agonist is 3-O-desacyl-4′-monophosphoryl lipid A (MPL), an adjuvant comprising MPL, or an outer membrane vesicle (OMV).

27. The method of claim 26 , wherein the OMV is a N. meningitidis, N. gonorrhoeae, Escherichia coli or Pseudomonas aeruginosa OMV.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2021
From: JEN, FREDA E.-C.; SEIB, KATE; SEMCHENKO, EVGENY; JENNINGS, MICHAEL
To: GRIFFITH UNIVERSITY
Reel/Frame 057356/0981 →
Priority Claims (1)
AU 2018904887 · Dec 21, 2018 · national
Continuity (1)
Related Publication 20220062402A1 · Mar 3, 2022
References Cited (79)
US 20060008476A1 · Pizza · 2006 [cited by applicant]
US 20120052092A1 · Exley et al. · 2012 [cited by applicant]
US 20120070457A1 · Daugherty · 2012 [cited by applicant]
WO WO1992005266 · 1992 [cited by applicant]
WO WO1995030763 · 1995 [cited by applicant]
WO WO1996037626 · 1996 [cited by applicant]
WO WO2002079243A2 · 2002 [cited by applicant]
WO WO2017123886A1 · 2017 [cited by applicant]
WO WO2018169926A1 · 2018 [cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Research, 1997, vol. 25, No. 17, pp. 3389-3402. [cited by applicant]
Alves et al., “Bacterial Nanobioreactors-Directing Enzyme Packaging into Bacterial Outer Membrane Vesicles,” ACS Applied Material & Interfaces, 2015, 7, pp. 24963-24972. [cited by applicant]
Bos et al., “Involvement of Neissseria meningitidis Lipoprotein GNA2091 in the Assembly of Subset of Outer Membrane Proteins,” The Journal of Biological Chemistry, May 30, 2014, vol. 289, No. 22 pp. 5602-15610. [cited by applicant]
Brandler et al., “A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus,” Vaccine 31, 2013, pp. 3718-3725. [cited by applicant]
Brot et al., “The Thioredoxin Domain of Neisseria gonorrhoeae PilB Can Use Electrons from DsbD to Reduce Downstream Methionine Sulfoxide Reductases,” The Journal of Biological Chemistry, Oct. 27, 2006, vol. 281, No. 43,… [cited by applicant]
Cantarella et al., “Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma,” Vaccine 27, 2009, pp. 3385-3390. [cited by applicant]
Choi et al., “Viral vectors for vaccine applications,” Clinical and Experimental Vaccine Research, 2013, 2, pp. 97-105. [cited by applicant]
Coler et al., “Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvnt System as a Vaccine Adjuvant,” Plos ONE, 2011, vol. 6, Issue 1, pp. 1-12. [cited by applicant]
Craig et al., “The potential impact of vaccination on the prevalence of gonorhea,” Vaccine33, 2015, pp. 4520-4525. [cited by applicant]
Devereux t al., “A comprhenive analysis programs for the VAX,” Nucleic Acids Research, 1984, vol. 12. No. 1. pp. 387-395. [cited by applicant]
Diethelm-Okita et al., “Universal Epitopes for Human CD4+ Cells on Tetanus and Diphtheria Toxins,” The Journal of Infectious Diseases, 2000, 181, 1001-1009. [cited by applicant]
Edwards et al.,“Is gonococcal disease preventable? The importance of understandingimmunity and pathogenesis in vaccine development,” Critical Reviews in Microbiology, 2016, 42:6, 928-941. [cited by applicant]
Ezraty et al.,“Methionine sulfoxide reductases in prokaryotes,” Biochimica et Biophysica Acta 1703, 2005, pp. 221-229. [cited by applicant]
Farris et al., “Micro- and nanoparticulates for DNA vaccine delivery,” Experimental Biology and Medicine, 2016, 241: 919-929. [cited by applicant]
Garçon et al., “From discovery to licensure, the Adjuvant System story,” Human Vaccines & Immunotherapeutics, 2017, vol. 13, No. 1, pp. 19-33. [cited by applicant]
GenBank, “Neisseria gonorrhoeae 1291 supercont1.3 genomic scaffold, whole genome shotgun sequence,” GenBank: DS999919.1, 2016. [cited by applicant]
Genpept, “Peptide methionine sulfoxide reductase msrA/msrB [Neisseria gonorrhoeae 1291],” GenBank: EEH61172.1, 2016. [cited by applicant]
Gerritzen et al., “Bioengineering bacterial outer membrane vesicles as vaccine platform,” Biotechnology Advances 35, 2017, pp. 565-574. [cited by applicant]
Gilbert, Sarah C., “Clinical development of Modified Vaccinia virus Ankara vaccines,” Vaccine 31, 2013, pp. 4241-4246. [cited by applicant]
Greenstein et al., “A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.,” The Journal of Immunology, Jun. 15, 1992, vol. 148, No. 12, pp. 3970-3977. [cited by applicant]
Gregory et al., “Vaccine delivery using nanoparticles,” Frontiers in Cellular and Infection Microbiology, Mar. 2013, vol. 3, Article 13, pp. 1-13. [cited by applicant]
Humphreys et al., “Novel viral vectors in infectious diseases,” Immunology, The Journal of cells, molecules, systems and technologies, 2017, 153, pp. 1-9. [cited by applicant]
Ieva et a., “CrgA Is an Inducible LysR-Type Regulator of Neisseria meningitidis, Acting both as a Repressor and as an Activator of Gene Transcription,” Journal of Bacteriology, May 2005, vol. 187, No. 10, pp. 3421-3430. [cited by applicant]
Jerse, Ann E., “Experimental Gonococcal Genital Tract Infection and Opacity Protein Expression in Estradiol-Treated Mice,” Infection and Immunity, Nov. 1999, vol. 67, No. 11, pp. 5699-5708. [cited by applicant]
Jerse, et al., “Vaccines against gonorrhea: Current status and future challenges,” Vaccine 32, 2014, pp. 1579-1587. [cited by applicant]
Joshi et al., “Targeting tumor antigens to dendritic cells using particulate carriers,” Journal of Controlled Release 161, 2012, pp. 25-37. [cited by applicant]
Krogh et al., “Predicting Transmembrane Protein Topology with a Hidden Markov Model: Aplication to Complete Genomes,” J. Mol. Biol., 2001, 305, pp. 567-580. [cited by applicant]
Lerner Richard A., “Combinatorial antibody libraries: new advances, new immunological|insights,” Department of Cell and Molecular Biology, The Scripps Research Institute, Aug. 2016, vol. 16, pp. 498-508. [cited by applicant]
Lowther e al., “The mirrored methionine sulfoxide reductases of Neisseria gonorrhoeae pilB,” Nature Sructural Biology, May 2002, vol. 9, No. 5, pp. 348-352. [cited by applicant]
Lundstrom, Kenneth, “Alphavirus Vectors in Vaccine Development,” Journal of Vaccines & Vaccination, 2012, vol. 3, Issue 3, pp. 1-8. [cited by applicant]
McQuillen et al., “Complement-Mediated Bacterial Killing Assays,” Methods in Enxymology, 1994, vol. 236, pp. 137-147. [cited by applicant]
Naso et al., “Adeno-Associated Virus (AAV) as a Vector for Gene Therapy,” BioDrugs, 2017, 31:317-334. [cited by applicant]
Packiam et al., “Mouse Strain-Dependent Differeencs in Susceptibility to Neisseria gonorrhoeae Infection and Induction of Innate Immune Responses,” Infection and Immunity, Jan. 2010, vol. v78, No. 1, pp. 433-440. [cited by applicant]
Petousis-Harris et al., “Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study,” Lancet, Sep. 30, 2017, vol. 390, pp. 1603-1610. [cited by applicant]
Pira et al., “High Throughput T Epitope Mapping and Vaccine Development,” Journal f Biomedecine and Biotechnology, 2010 vol. 2010, Article ID 325720, pp. 1-12. [cited by applicant]
Power et al., “The Phase-Variable Allele of the Pilus Glycosylation Gene pglA Is Not Strongly Associate with Strains of Neisseria gonorrhoeae Isolated from Patients with Disseminated Gonococcal Infection,” Infection and… [cited by applicant]
Rice et al., “Neisseria gonorrhoeae: Drug Resistance, Mouse Models, and Vaccine Development,” Annual Review of Microbiology, 2017, vol. 71, pp. 665-686. [cited by applicant]
Romero-Steiner et al., “Standardization of an Opsonophagocytic Assay for the Measurement of Functional Antibody Activity against [cited by applicant]
Seib et al., “Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection,” Vaccine 28, 2010, pp. 2416-2427. [cited by applicant]
Semchenko et al., “MetQ of Neisseria gonorrhoeae Is a Surface-Expressed Antigen ThatElicits Bactericidal and Functional Blocking Antibodies,” Infection and Immunity, Feb. 2017, vol. 85, Issue 2, pp. 1-17. [cited by applicant]
Steichen et al., “Gonococcal Cervicitis: A Role for Biofilm in Pathogenesis,” Joural of Infectious Diseases, Dec. 15, 2008, 198, pp. 1856-1861. [cited by applicant]
Steinhagen et al., “TLR-based immune adjuvants,” Vaccine 29, 2011, pp. 3341-3355. [cited by applicant]
Tan et al.,“Outer Membrane Vesicles: Current Status and Future Direction of These Novel Vaccine Adjuvants,” Frontiers in Microbiology, Apr. 2018, vol. 9, Article 783, pp. 1-12. [cited by applicant]
Tomusange et al., “Engineering human rhinovirus serotype-A1 as a vaccine vector,” Virus Research 203, 2015, pp. 72-76. [cited by applicant]
UniProtKB/Swiss-Prot., P14930, Peptide methionine sulfoxide reductase MsrA/MsrB, 1990. [cited by applicant]
Ura et al., “Developments in Viral Vector-Based Vaccines,” Vaccines, 2014, 2, pp. 624-641. [cited by applicant]
Vincent et al., “Biological feasibility and importance of a gonorrhea vaccine for global public health,” Vaccine 37, 2019, pp. 7419-7426. [cited by applicant]
Virji et al.,“Opc- and pilus-dependent interactions of meningococci with human endothelial cells: molecular mechanisms and modulation by surface polysaccharides,” Molecular Microbiology, 1995, 18(4), pp. 741-754. [cited by applicant]
Wagner et al.,“Liposome Technology for Industrial Purposes,” Journal of Drug Delivery, vol. 2011, Article ID 591325, pp. 1-9. [cited by applicant]
Weissbach t al., “Methionine sulfoxide reductases: history and cellular role in protecting against oxidative damage,” Biochimica et Biophysica Acta 1703, 2005, pp. 203-212. [cited by applicant]
Weyand, Nathan J., “Neisseria models of infection and persistence in the upper respiratory tract,” Pathogens and Disease, 2017, vol. 75, No. 3, pp. 1-13. [cited by applicant]
Yi et al., “Development and Evaluation of an Improved Mouse Model of Meningococcal Colonization,” Infection and Immunity, Apr. 2003, vol. 71, No. 4, pp. 1849-1855. [cited by applicant]
Yu et al., “Microfluidic Methods for Production of Lipsomes,” Methods in Enzymology, 2009, vol. 465, pp. 129-140. [cited by applicant]
Zhang et al.,“Adenoviral vector-based strategies against infectious disease and cancer,” Human Vaccines & Immunotherapeutics, 2016, vol. 12, No. 8, pp. 2064-2074. [cited by applicant]
Zhao et al., “Nanoparticle vaccines,” Vaccine 32, 2014, pp. 327-337. [cited by applicant]
Boschi-Muller, S., Molecular Mechanisms of the Methionine Sulfoxide Reductase System from Neisseria meningitidis, Antioxidants, vol. 7, No. 131, 11 pages, 2018. [cited by applicant]
Brot et al., The Thioredoxin Domain of Neisseria gonorrhoeae PilB Can Use Electrons from DsbD to Reduce Downstream Methionine Sulfoxide Reductases, The Journal of Biological Chemistry, vol. 281, No. 43, pp. 32668-32675,… [cited by applicant]
Lowther et al., Thiol-disulfide exchange is involved in the catalytic mechanism of peptide methionine sulfoxide reductase, PNAS, vol. 97, No. 12, pp. 6463-6468, 2000. [cited by applicant]
Lowther et al., The mirriored methionione sulfoxide reductases of Neisseria gonorrhoeae pilB, Nature Structural Biology, vol. 9, No. 5, pp. 348-352, 2002. [cited by applicant]
Peptide methionine sulfoxide reductase msrA/msrB [Neisseria gonorrhoeae 1291] GenBank: EEH61172.1, 2016. [cited by applicant]
Full=Peptide methionine sulfoxide reductase MsrA/MsrB UniProtKB/Swiss-Prot: P14930.2, 1990. [cited by applicant]
Wu et al., The N-terminal Domain of PILB from Neisseria meningitidis is a Disulfide Reductase That Can Recycle Methionine Sulfoxide Reductases, The Journal of Biological Chemistry, vol. 280, No. 13, pp. 12344-12350, 200… [cited by applicant]
Quintemet et al., Formation of the Complex between DsbD and PilB N-Terminal Domains from Neisseria meningitidis Necessitates an Adaptability of nDsbD, Structure, vol. 17, pp. 1024-1033, 2009. [cited by applicant]
UniProt database protein Q5F571 (Q5F571_NEIG1), Version 100, dated Feb. 28, 2018, Retrieved from: https://rest.uniprot.org/unisave/Q5F571?format=txt&versions=100. [cited by applicant]
UniProt database protein Q5F571 (Q5F571_NEIG1), Version 98, dated Feb. 28, 2018, Retrieved from: https://rest.uniprot.org/unisave/Q5F571?format=txt&versions=100. [cited by applicant]
Freda E.-C. et al., The Neisseria gonorrhoeae Methionine Sulfoxide Reductase (MsrA/B) Is a Surface Exposed, Immunogenic, Vaccine Candidate, Frontiers in Immunology, vol. 10, Article 137, pp. 1-9, 2019. [cited by applicant]
Skaar et al., The outer membrane localization of the Neisseria gonorrhoeae MsrA/B is involved in survival against reactive oxygen species, Proceedings of the National Academy of Sciences of the United States of America,… [cited by applicant]
International Search Report mailed on Mar. 6, 2020 in International Application No. PCT/AU2019/051418. [cited by applicant]
Written Opinion mailed on Mar. 6, 2020 in International Application No. PCT/AU2019/051418. [cited by applicant]
International Preliminary Report on Patentability mailed on Jul. 1, 2021 in International Application No. PCT/AU2019/051418. [cited by applicant]